[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-subjects-hs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-subjects-hs":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,44,71,93,126,147,169,211,247,268,289,310,331,354,374,398,420],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644490","methodological-study-of-exercise-and-hypoxic-conditions-in-healthy-subjects-100644490",false,"NCT07671638","Methodological Study of Exercise and Hypoxic Conditions in Healthy Subjects","ExHyp","Inclusion Criteria:\n\n* Healthy male or female volunteers\n* Aged 18-55\n* Body Mass Index \\\u003C30 kg\u002Fm²\n* Participants covered by a social security scheme\n* Participants capable of signing an informed consent form\n* Negative pregnancy test and highly effective contraception for women of childbearing age\n\nExclusion Criteria:\n\n* Cardiorespiratory, metabolic and neurological disorders, or other conditions assessed during the inclusion consultation that may affect physiological responses to exercise or hypoxia\n* Pharmacological treatment taken during the study, other than oral or implantable contraceptive medication for female volunteers of childbearing age",true,"ALL","18 Years","55 Years",{"count":21,"type":22},305,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this protocol is to assess physiological responses during various physical exercise protocols (whole-body exercise such as cycling or treadmill running, or localised exercise such as knee extension) and during inhalation of a gas mixtures with various oxygen contents (similar to exposure at high altitude).",[28,29,30],"Healthy Subjects (HS)","Exercise","Hypoxia","NOT_YET_RECRUITING","2026-06-22",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":22},"2026-06-15",{"date":39,"type":22},"2031-12-31",{"name":41,"class":42},"University Hospital, Grenoble","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100641469","phase-1-a-phase-1-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-ism8969-100641469","NCT07581431","A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of ISM8969 in Healthy Adult and Elderly Participants and Obese Adult Participants at Risk of Cardiovascular Disease","Inclusion Criteria:\n\nParticipants must meet all the following criteria to be included in the study:\n\nInclusion criteria 1\\~4 are only for the healthy participants in the SAD and MAD study:\n\n1. Male or female participants, including adult participants (≥18 and \\\u003C65 years of age) for the SAD cohorts 1-6 and MAD cohorts 1-3, and elderly participants (≥65 and ≤80 years of age) for MAD cohort 4.\n2. Body mass index (BMI) \\>18.5 and \\\u003C30.0 kg\u002Fm2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.\n3. Non-smokers (no use of tobacco or nicotine products within 1 month prior to screening).\n4. Healthy as defined the current protocol.\n\n   Inclusion criteria 5\\~9 are only for the obese participants at risk of cardiovascular disease in MAD study):\n5. Male or female, ≥18 and ≤65 years of age.\n6. 30.0 kg\u002Fm2 ≤ BMI \\\u003C 42.0 kg\u002Fm2.\n7. No change in body weight or self-reported change of less than 5.0% within 3 months before screening.\n8. Presence of 1 or more risk factors for cardiovascular disease such as hypertension, hyperlipidemia. If present, must be controlled with stable medication dose\u002Ftherapy (defined as a stable medication dose\u002Ftherapy for 3 months or longer).\n9. hsCRP ≥3 mg\u002FL.\n\nExclusion Criteria:\n\nParticipants for whom any of the following applies will be excluded from the study:\n\n1. Columbia suicide severity rating scale (C-SSRS) score above Type 1 ideation.\n2. Positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen and antibody, treponema pallidum antibody or QuantiFERON®-TB test at screening.\n3. Positive pregnancy test or lactating female participant.\n4. History of any central nervous system (CNS) disorder or history of seizure of any cause.\n5. Clinically significant 12-lead ECG, physical examination, vital signs or laboratory abnormalities at screening, including but not limited to defined in the protocol.\n6. History of significant cardiovascular or cerebrovascular disease within 6 months before screening, including but not limited to defined in the protocol.\n7. History of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, or in situ carcinomas of the cervix) for less than 5 years; or there is a potential malignancy during screening.\n8. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days (or 5 half-lives, whichever is longer) prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days (or 5 half-lives, whichever is longer) prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.\n9. Presence of contraindication to lumbar puncture or lumbar catheter as judged by Investigator.","80 Years",{"count":53,"type":22},100,[55],"PHASE1","This is a single center, phase 1, randomized, double-blind, placebo-controlled sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of ISM8969 in healthy adults and elderly participants and obese adult participants at risk of cardiovascular disease.",[28,58],"Obese Adult Participants at Risk of Cardiovascular Disease",[60,61],"NLRP3 Inhibitor","ISM8969","RECRUITING","2026-06-17",{"date":32,"type":35},{"date":37,"type":35},{"date":67,"type":22},"2027-03-31",{"name":69,"class":70},"InSilico Medicine Hong Kong Limited","INDUSTRY",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100637342","early-phase-1-multi-organ-imaging-of-microvascular-and-metabolic-function-100637342","NCT07604207","Multi-organ Imaging of Microvascular and Metabolic Function","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* For patients with cardiovascular disease: Documented diagnosis of ischemic heart disease based on standard clinical, radiologic, and\u002For histopathologic criteria, as documented in the medical record; or a clinical nuclear cardiac stress PET test within 1 year.\n* For healthy subjects: No diagnosis of cardiometabolic disease, cancer, or other major disease within the past 5 years\n\nExclusion Criteria:\n\n* Contraindications to PET due to:\n\n  1. Research-related radiation exposure exceeding current MGB Radiology Department guidelines (i.e., 50 mSv in the prior 12 months);\n  2. Inability to lie comfortably on the bed inside the scanner;\n  3. Body weight \\> 300 lbs (weight limit of the scanner table);\n  4. Pregnancy or breastfeeding;\n* Individuals with fasting plasma glucose level of \\>200 mg\u002FdL;\n* Claustrophobia\n* Employed under the direct supervision of the PI conducting the research.",{"count":78,"type":22},60,[80],"EARLY_PHASE1","What if heart disease starts outside the heart? This research will study how to simultaneously assess brain and body physiology, how they are jointly related to heart function, and how their response to physical and mental stress differs in patients with heart disease.",[28,83],"Cardiovascular Diseases (CVD)","2026-05-18",{"date":86,"type":35},"2026-05-22",{"date":88,"type":22},"2026-07",{"date":90,"type":22},"2031-07",{"name":92,"class":42},"Massachusetts General Hospital",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":16,"sex":17,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":110,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100635218","sebum-metabolomics-and-lipidomics-for-clinical-applications-100635218","NCT07549828","Sebum Metabolomics and Lipidomics for Clinical Applications","Development of a Sample Collection Protocol and a Metabolomics\u002FLipidomics Analytical Strategy for Investigating Sebum and Its Clinical Applications","A. Healthy Participants\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be in good health and suitable for participation.\n* No diagnosed skin diseases or chronic systemic diseases.\n* No use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Presence of acute or chronic skin diseases, or chronic systemic diseases.\n* Use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nB. Participants with Skin Diseases or Specific Skin Conditions\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.\n* Diagnosed by a physician or clinically assessed as having one of the following:\n\n  * Acne\n  * Atopic dermatitis\n  * Seborrheic dermatitis\n  * Psoriasis\n  * Other common skin diseases\n  * Specific skin conditions (e.g., postmenopausal or aging-related skin changes)\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Severe disease that may compromise skin integrity or pose a risk to participant safety.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nC. Participants Receiving Dermatological Treatments or Using Skincare Products\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.\n* Participants who, based on clinical needs or daily routines, are currently using or are expected to use or receive any of the following:\n\n  * Physician-prescribed topical dermatological medications\n  * Physician-prescribed systemic therapies (oral or injectable)\n  * Routine use of general skincare products\n  * Physician-directed non-invasive dermatological treatments\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Severe disease that may compromise skin integrity or pose a risk to participant safety.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nD. Healthy Participants Undergoing Short-term Antibiotic Intervention\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity.\n* Assessed by the investigator to be healthy, with skin condition suitable for the intervention used in this study.\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Known allergy or adverse reactions to the study intervention drug (topical antibiotic ointment containing bacitracin, polymyxin B, and neomycin).\n* Presence of visible skin disease, wounds, infection, inflammation, or other abnormal skin conditions at the sampling site.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.","20 Years",{"count":102,"type":22},200,[25],"This study aims to develop a standardized workflow for sebum sampling and metabolomics\u002Flipidomics analysis using Sebutape. A total of 200 participants will be recruited, including healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention. The study will investigate sebum composition, skin microbiome profiles, and their interactions under different conditions to explore potential biomarkers and clinical applications.",[106,107,108,109,28],"Acne","Atopic Dermatitis","Seborrheic Dermatitis","Psoriasis",[111,112,113,114,115,116],"Sebum","Lipidomics","Metabolomics","Skin microbiome","Sebutape","LC-MS\u002FMS","2026-04-17",{"date":119,"type":35},"2026-04-24",{"date":121,"type":22},"2026-04-01",{"date":123,"type":22},"2029-03-31",{"name":125,"class":42},"National Taiwan University Hospital",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":43},"100633596","vagus-nerve-stimulation-for-reaction-time-100633596","NCT07528742","Vagus Nerve Stimulation for Reaction Time","Enhancing Reaction Time Through Non-Invasive Vagus Nerve Stimulation","Inclusion Criteria:\n\n* Healthy participants over the age of 18\n* did not receive vagus nerve stimulation previously\n\nExclusion Criteria:\n\n* alcohol or drug abuse\n* metal in the skull\n* implanted cardiac or cranial devices\n* Women during 3 trimester of pregnancy",{"count":134,"type":22},30,[25],"Non-Invasive Vagus Nerve Stimulation will be provided to the participants using a transcutaneous electrical nerve stimulation (TENS) unit, a routine physical therapy intervention by the faculty researcher who is a licensed physical therapist. The electrodes will be clipped to ear over the vagus nerve distribution area. The parameters will be 30 Hz, 250 us, 5 minutes, at tolerance (no pain). Reaction time will test collected pre and post the stimulation using online reaction time testing platform.",[28],"2026-04-09",{"date":140,"type":35},"2026-04-14",{"date":142,"type":22},"2026-04-06",{"date":144,"type":22},"2027-04-05",{"name":146,"class":42},"Youngstown State University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":165,"leadSponsor":167,"locationsCount":43},"100632665","phase-1-first-in-human-study-of-ish0613-safety-tolerability-pharmacokinetics-and-pharmacodynamics-100632665","NCT07516639","First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics","A Randomized, Double-Blind, Placebo-Controlled Phase Ia First-in-Human Study to Evaluate the Single Intravenous Administration of ISH0613 in Healthy Subjects","Inclusion Criteria:\n\n1. Healthy Chinese adult subjects, male or female, aged 18 to 45 years (inclusive);\n2. Body mass index (BMI) between 19.0 and 28.0 kg\u002Fm² (inclusive); body weight generally ≥50 kg for males and ≥45 kg for females;\n3. Male subjects and their partners, or female subjects, must agree to use at least one effective non-pharmacological contraceptive method (e.g., complete abstinence, intrauterine device, partner sterilization) during the study period, and must have no plan for sperm or egg donation;\n4. Subjects are able to fully understand the purpose, nature, and procedures of the study, including potential adverse reactions, and voluntarily sign the informed consent form (ICF);\n5. Subjects are able to communicate well with the investigator and are willing and able to comply with all study procedures and requirements.\n\nExclusion Criteria:\n\n1. Known allergy to the investigational product or any of its excipients, or a history of hypersensitivity to monoclonal antibodies;\n2. History or presence of clinically significant diseases of the cardiovascular, endocrine, nervous, gastrointestinal, respiratory, genitourinary, hematological, immunological, psychiatric, or metabolic systems, or any other condition that may interfere with study results, as judged by the investigator;\n3. Clinically significant abnormalities in laboratory tests (hematology, urinalysis, biochemistry, coagulation) or auxiliary examinations (chest X-ray, abdominal ultrasound);\n4. Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus (HIV) antibody, or syphilis antibody;\n5. Receipt of any surgical procedure within 6 months prior to signing the informed consent form, or planned surgery (including cosmetic, dental, or oral surgery) within 2 weeks after the end of the study;\n6. Alcohol consumption exceeding 14 units per week within 3 months prior to screening (1 unit = 360 mL beer, 150 mL wine, or 45 mL liquor), or positive alcohol breath test at screening or baseline, or inability to abstain from alcohol during the study;\n7. Average smoking of more than 5 cigarettes per day within 3 months prior to screening;\n8. History of drug abuse, use of soft drugs (e.g., cannabis) within 3 months prior to screening, or use of hard drugs (e.g., cocaine, phencyclidine) within 1 year prior to screening, or positive drug abuse screening test (including morphine, ketamine, THC-COOH, methamphetamine, MDMA, cocaine);\n9. Habitual excessive intake within 4 weeks prior to screening of caffeine-containing beverages or foods or substances that may affect drug metabolism, such as coffee (\\>1100 mL\u002Fday), tea (\\>2200 mL\u002Fday), cola (\\>2200 mL\u002Fday), energy drinks (\\>1100 mL\u002Fday), or chocolate (\\>510 g\u002Fday);\n10. Use of any prescription drugs, over-the-counter medications, or traditional Chinese medicines within 14 days prior to dosing;\n11. Receipt of any monoclonal antibody therapy within 6 months prior to dosing;\n12. Vaccination within 3 months prior to dosing, or planned vaccination during the study period;\n13. Participation in another clinical trial and receipt of investigational drug treatment within 3 months prior to dosing;\n14. Blood donation or significant blood loss (\\>400 mL, excluding menstrual loss) within 3 months prior to screening, or receipt of blood transfusion or blood products, or planned blood donation during the study period or within 1 month after study completion;\n15. Pregnant or lactating women;\n16. Clinically significant abnormal vital signs (systolic blood pressure \\\u003C90 mmHg or ≥140 mmHg; diastolic blood pressure \\\u003C55 mmHg or ≥90 mmHg; heart rate \\\u003C50 bpm or \\>100 bpm; body temperature \\\u003C35.4°C or \\>37.3°C), or clinically significant ECG abnormalities (QTcF \\>450 ms for males, \\>470 ms for females), or clinically significant findings on physical examination, as judged by the investigator;\n17. Presence of infection requiring treatment for acute or chronic infection, including but not limited to:\n\n    1. Herpes zoster within 12 months prior to screening;\n    2. Current suppressive therapy for chronic infections (e.g., tuberculosis, Pneumocystis, cytomegalovirus, herpes simplex virus, varicella-zoster virus, or atypical mycobacteria);\n    3. History of tuberculosis or contact with active tuberculosis within 6 months prior to screening, or positive T-SPOT test;\n    4. Parasitic infection within 3 months prior to dosing;\n    5. Hospitalization due to infectious disease within 30 days prior to dosing;\n    6. Parenteral anti-infective treatment (including antibacterial, antiviral, antifungal, or antiparasitic agents) within 30 days prior to dosing;\n18. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.","45 Years",{"count":156,"type":22},26,[55],"The goal of this clinical trial is to learn about a study drug called ISH0613 and how it behaves in healthy adults.\n\nThis study will also evaluate the safety and tolerability of ISH0613 after a single intravenous (IV) dose.\n\nThe main questions this study aims to answer are:\n\nI. What medical problems (side effects) may occur after receiving ISH0613? How does ISH0613 move through and get processed in the body? II. Does ISH0613 affect certain biological markers related to the immune system? III. Researchers will compare ISH0613 to a placebo (a look-alike substance that contains no active drug) to better understand its effects.\n\nParticipants will:\n\nI. Receive a single intravenous infusion of either ISH0613 or placebo II. Stay in the clinical unit for several days for close monitoring after dosing III. Return to the clinic for follow-up visits over several weeks IV. Provide blood samples for safety checks and laboratory testing V. Be monitored for any side effects throughout the study",[28,160],"SLE (Systemic Lupus)","2026-04-07",{"date":163,"type":35},"2026-04-13",{"date":121,"type":22},{"date":166,"type":22},"2026-12-31",{"name":168,"class":70},"SUNHO（China）BioPharmaceutical CO., Ltd.",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":178,"phases":4,"briefSummary":179,"conditions":180,"keywords":185,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":210},"100581157","exploring-the-olfactory-mucosa-blood-and-urine-for-the-identification-of-early-biomarkers-of-parkinsons-disease-atypical-parkinsonisms-and-neurocognitive-disorders-due-to-lewy-body-disease-100581157","NCT06846658","Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease","EXTRAORDINARY","Inclusion Criteria:\n\n* PD (Postuma et al., 2015), MSA (Palma et al., 2018), DLB (McKeith et al., 2017), OND including acquired and hereditary ataxic syndrome with known etiology, progressive supranuclear palsy, corticobasal degeneration, and motor neuron disease.\n\nExclusion Criteria:\n\n* na",{"count":177,"type":22},180,"OBSERVATIONAL","Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages. Each disease is associated with distinct conformers of misfolded alpha-synuclein (maS) which form typical protein aggregates in the brain and represent key disease biomarkers. Thus, detection and characterization of intracerebral maS aggregates allow a definite diagnosis. The recent development of ultrasensitive assays enabled the detection of maS and other potential new biomarkers in peripheral tissues, although with several limitations. Here, the investigators propose to combine the expertise of leading and young researchers in the field of neurology, structural and molecular biology, biophysics and machine learning to perform ultrasensitive and multi-omics analyses of olfactory mucosa (OM), blood and urine of PD, MSA and DLB patients for detecting and characterizing key peripheral biomarkers allowing accurate disease recognition.",[181,182,183,184,28],"Parkinson Disease","MSA - Multiple System Atrophy","Lewy Body Dementia (LBD)","Neurodegenerative Disease",[186,187,188,189,190,191,192,193,194,195,196,197,198,199,200],"Parkinson's disease (PD)","multiple system atrophy (MSA)","dementia with Lewy bodies (DLB)","misfolded alpha-synuclein","new biomarkers","peripheral tissues","Real-Time Quaking-Induced Conversion (RT-QuIC)","single-molecule array (Simoa)","circulating neurofilament light chain (NfL)","Nanoparticle Tracking Analysis (NTA)","blood-derived extracellular vesicles (EVs)","multi-omics analyses","transmission electron microscopy (TEM) and protein-NMR","protein misfolding","early diagnosis","2026-03-25",{"date":203,"type":35},"2026-03-30",{"date":205,"type":35},"2023-10-03",{"date":207,"type":22},"2026-04",{"name":209,"class":42},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",3,{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":16,"sex":17,"minAge":100,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":230,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":246},"100613193","effect-of-hydrogen-gas-on-hyperbaric-oxygen-toxicity-100613193","NCT07263399","Effect of Hydrogen Gas on Hyperbaric Oxygen Toxicity","Effect of Hydrogen Gas on Hyperbaric Oxygen Toxicity - A Randomized Controlled Cross-Over Trial","Inclusion Criteria:\n\n* Military divers actively serving, aged 20-64 years\n* Meeting the Swedish Armed Forces physical standards for diving\n\nExclusion Criteria:\n\n* Ongoing infection or illness that may impact pulmonary function\n* Use of alcohol or smoking cigarettes within 48 hours\n* Diving with any breathing gas within 48 hours\n* Diving with oxygen-enriched gas (100% O₂) within 2 weeks\n* Use of medications that could affect oxidative stress, lung function, or neurological status\n* Medical history of serious diving-related injuries or long-term complications","64 Years",{"count":220,"type":22},32,[25],"The goal of this trial is to investigate whether adding a small fraction of hydrogen gas to an oxygen-enriched breathing mixture can reduce pulmonary oxygen toxicity (POT) in healthy and active divers from the Swedish Armed Forces. The main questions it aims to answer are:\n\n* Does hydrogen gas reduce oxidative stress and changes in pulmonary function associated with prolonged hyperbaric oxygen exposure?\n* What are the underlying pathophysiological mechanisms of pulmonary oxygen toxicity?\n\nResearchers will compare oxygen-enriched breathing gas with 1-2% hydrogen to oxygen-enriched gas with 1-2% nitrogen (control) to see if hydrogen provides protective effects against POT during hyperbaric exposure.\n\nParticipants will:\n\n* Complete two hyperbaric exposure sessions (hydrogen vs. nitrogen), each lasting 240 minutes at 1.75 ATA\n* Undergo pulmonary function tests and sampling of blod and urin before and after each session\n* Serve as their own controls in a double-blind, randomized, crossover study design",[224,225,226,227,28,228,229],"Oxygen Toxicity","Oxidative Stress","Hyperoxia","Hyperbaric Oxygen","Diving Medicine","Hydrogen-oxygen Gas",[231,232,233,234,227,235,236],"Pulmonary Oxygen Toxicity","Hydrogen Gas","Diving Physiology","Lung Function","Human Study","Military Divers","2025-12-01",{"date":239,"type":35},"2025-12-04",{"date":241,"type":22},"2026-01",{"date":243,"type":22},"2030-12",{"name":245,"class":42},"Blekinge Institute of Technology",2,{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":43},"100611541","phase-1-a-single-ascending-dose-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-syh2070-injection-100611541","NCT07241923","A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection","A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2070 Injection in Healthy Subjects","Inclusion Criteria:\n\n1. Subjects must provide informed consent before the trial, fully understand its content, procedures, and potential adverse reactions, and voluntarily sign the written ICF;\n2. Sex: Male or female;\n3. Age: 18-60 years (inclusive);\n4. Body mass index (BMI) in the range of 19 to 30 kg•m\\^2 \\[BMI = weight\u002Fheight\\^2 (kg•m\\^2)\\] (inclusive), with a weight of no less than 50 kg for males (inclusive) and no less than 45 kg for females (inclusive);\n5. Fasting serum TG ≥150 mg\u002FdL (1.7 mmol\u002FL) and ≤ 500 mg\u002FdL (5.6 mmol\u002FL), and LDL-C ≥70 mg\u002FdL (1.8 mmol\u002FL) and \\\u003C 190 mg\u002FdL (4.9 mmol\u002FL) during the screening and baseline periods;\n6. Subjects must maintain stable die, exercise, and other lifestyle habits from 4 weeks prior to screening until the end of the study, with no planned changes to diet, exercise or weight loss programs;\n7. Subjects must be able to communicate well with the investigator and can complete the study according to the protocol requirements.\n\nExclusion Criteria:\n\n1. History of severe allergic diseases or allergic constitution (≥ 3 drug or food allergies), or known history of allergy to the investigational drug components (N-acetylgalactosamine, sodium hydroxide, phosphoric acid) or oligonucleotide drugs;\n2. Use of antibody drugs and\u002For oligonucleotide drugs targeting PCSK9\u002FANGPTL3\u002FApoC-III within 12 months prior to screening;\n3. Current and\u002For history of clinically significant medical conditions, including but not limited to circulatory, hematological or hematopoietic, respiratory, endocrine, urinary, digestive system diseases, neurological or psychiatric disorders, infections, tumors, severe trauma, or any other disease that should be excluded or may interfere with the interpretation of the study results, as judged by the investigator;\n4. History of major surgery within 6 months prior to screening, or are scheduled to undergo major surgery during the course of the study;\n5. History of bariatric surgery within 12 months prior to screening;\n6. Have clinically significant abnormalities in vital signs, physical examination, electrocardiogram, and laboratory tests (excluding lipid parameters);\n7. Estimated glomerular filtration rate (eGFR) \\\u003C90 mL\u002Fmin\u002F1.73 m\\^2 at screening;\n8. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) \\>1.5× upper limit of normal (ULN) at screening (one retest allowed within 1 week);\n9. Prolonged QT \u002F QTc interval at screening or baseline (QTcF \\> 450 ms);\n10. Positive result for any of HBsAg, HCV antibody, syphilis antibody, and HIV antibody;\n11. Blood loss or donation \\>200 mL within 3 months prior to screening (excluding menstruation for females), and\u002For platelet donation within 2 weeks;\n12. Use of any drugs, health supplements, vitamins, or dietary supplements known to affect lipid metabolism within the longer of either: (a) 28 days prior to dosing; (b) 7 half-lives of the drug; (3) the duration of the agent's pharmacological effect, including but not limited to statins, fish oil, high-purity omega-3, prescription-dose niacin, fibrates, or anti-estrogen therapy;","60 Years",{"count":256,"type":22},48,[55],"This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2070 injection when administered subcutaneously to healthy subjects.",[28],"2025-11-28",{"date":237,"type":35},{"date":263,"type":35},"2025-11-15",{"date":265,"type":22},"2027-11-01",{"name":267,"class":70},"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":4},"100597949","phase-1-evaluation-of-627-in-healthy-adult-subjects-100597949","NCT07065136","Evaluation of 627 in Healthy Adult Subjects","A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SSGJ-627 in Healthy Adult Subjects","Inclusion Criteria:\n\n* Able to understand protocol requirements and sign a written ICF.\n* Male or female subjects aged 18-45 years when signing the ICF.\n* Male subjects with body weight ≥ 50 kg, and female subjects with body weight ≥ 45 kg. Subjects with BMI between 18 and 28 kg\u002Fm2.\n* Subjects whose test results are normal, or abnormal without clinical significance as determined by the investigator.\n* Female subjects with childbearing potential and male subjects (and their female partners) must agree to take highly effective contraceptive measures.\n\nExclusion Criteria:\n\n* History of severe allergy, or with a history of allergy to the study treatment or related excipients.\n* History of of significant alcohol abuse.\n* History of significant drug abuse.\n* Subjects who have positive result for urine nicotine test at screening.\n* Pregnant, or nursing females.",{"count":276,"type":22},108,[55],"This is a randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose phase I clinical study to evaluate the safety, tolerability, PK and immunogenicity of SSGJ-627 in healthy adult subjects after single subcutaneous injection.",[28],"2025-07-14",{"date":282,"type":35},"2025-07-15",{"date":284,"type":22},"2025-07-20",{"date":286,"type":22},"2026-09-18",{"name":288,"class":70},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":4},"100594935","phase-1-a-phase-1-mass-balance-study-of-csss17-in-healthy-chinese-males-100594935","NCT07025915","A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males","A Mass Balance Study of [14C]SSS17 in Healthy Chinese Male Subjects","Inclusion Criteria:\n\n1. Healthy adult male subjects aged 18-45 years .\n2. Body weight ≥50 kg .\n3. Normal findings on comprehensive health assessment.\n4. The subject demonstrates understanding of the trial's objectives, requirements, procedures, and potential adverse reactions; voluntarily participates; commits to complete all trial activities per protocol and comply with study regulations; with the informed consent process conducted in compliance with Good Clinical Practice .\"\n\nExclusion Criteria:\n\n1. Subjects with abnormalities in the nervous system, respiratory system, cardiovascular system, digestive system, hematological and lymphatic systems, endocrine system, or musculoskeletal system that are deemed clinically significant by the investigator.\n2. History of organic heart disease\n3. History of hypersensitivity or allergy to active ingredients.\n4. Average daily smoking \\>5 cigarettes within 3 months prior to screening or inability to abstain during the trial.\n5. Average weekly alcohol intake \\>14 units within 3 months prior to screening or positive alcohol breath test.\n6. History of drug abuse or illicit drug use, or positive urine drug screen.\n7. Participation in any other investigational drug trial within 3 months prior to screening.\n8. Use of any prescription\u002Fnon-prescription medication within 2 weeks prior to investigational product administration.\n9. History of needle\u002Fphobia or inability to tolerate venipuncture.\n10. Hemorrhoids\u002Factive perianal bleeding, chronic constipation\u002Fdiarrhea or positive fecal occult blood test at screening.\n11. Occupational radiation exposure;\n12. Pregnancy plans during or within 1 year post-trial, or refusal to use strict contraception by subject\u002Fpartner during and within 1 year post-trial.",{"count":297,"type":22},6,[55],"This study aims to evaluate the absorption, metabolism, and excretion of a single oral dose of \\[¹⁴C\\]SSS17 in healthy adult Chinese male subjects, elucidating its overall pharmacokinetic profile in humans to provide essential information for its rational clinical use.",[28],"2025-06-19",{"date":303,"type":35},"2025-06-25",{"date":305,"type":22},"2025-06",{"date":307,"type":22},"2025-07",{"name":309,"class":70},"Shenyang Sunshine Pharmaceutical Co., LTD.",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":43},"100584065","aftereffects-of-pes-preconditioned-with-rtms-on-the-human-pharyngeal-motor-cortex-100584065","NCT06884488","Aftereffects of PES Preconditioned with RTMS on the Human Pharyngeal Motor Cortex","Effect of Preconditioning of Human Pharyngeal Motor Cortex by Low Frequency Repetitive Transcranial Magnetic Stimulation on Enhancing Cortical Excitability Induced by Pharyngeal Electrical Stimulation","Inclusion Criteria:\n\nHealthy volunteers over the age of 18 will be recruited through adverts placed around Salford Royal Hospital, on a University of Manchester website which advertises for research volunteers and through a departmental database of volunteers who have expressed an interest in future research. There is no upper age limit for potential participants.\n\nExclusion Criteria:\n\nThe presence or a history of:\n\n1. Epilepsy\n2. Cardiac pacemaker\n3. Previous brain surgery\n4. Previous swallowing problems\n5. The use of medication which acts on the central nervous system\n6. Any implanted metal in the head\n7. Pregnancy (self-declared)",{"count":318,"type":22},14,[25],"The goal of this interventional study is to optimize the excitatory brain effects of combined neuromodulatory therapies on swallowing areas of the brain. The main question it aims to answer is:\n\nDoes preconditioning with 1 Hertz (Hz) repetitive transcranial magnetic stimulation (rTMS) delivered over hemispheric pharyngeal areas enhance the activating effects of pharyngeal electrical stimulation (PES) on cortical excitability?\n\nParticipants will:\n\n* Visit the department three times, with at least a one-week gap between visits.\n* Undergo baseline measurements for Pharyngeal motor evoked potential (PMEP) and Thenar motor evoked potential (TMEP), involving an electromyography (EMG) pharyngeal catheter inserted into the pharynx and gel electrodes to detect muscle activity.\n* Be randomly allocated to one of the three preconditioning-conditioning procedures during each visit : 1Hz rTMS followed by 5Hz PES, sham 1Hz rTMS followed by 5Hz PES, and 1Hz rTMS followed by sham 5Hz PES\n\n  1. Real rTMS will involve a figure-of-eight coil flat against the head delivering 1Hz stimulation at 90% of the thenar resting motor threshold.\n  2. Sham rTMS will involve holding the coil perpendicular to the scalp to prevent brain stimulation.\n  3. PES will involve a catheter delivering 0.2-ms pulses at 5Hz and 75% of the maximal tolerated intensity for 10 minutes. Sham PES will involve deactivating the current generator.\n* Complete PMEP and TMEP measurements at baseline before intervention and every 15 minutes from 0 - 60 minutes after the rTMS-PES procedure.\n* Complete a survey regarding tolerability and safety at the end of each visit.",[28],"2025-03-13",{"date":324,"type":35},"2025-03-19",{"date":326,"type":35},"2024-09-14",{"date":328,"type":22},"2025-08-31",{"name":330,"class":42},"University of Manchester",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":17,"minAge":254,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":352,"locationsCount":43},"100575634","self-initiated-perturbation-based-training-in-older-adults-100575634","NCT06774833","Self-initiated Perturbation-based Training in Older Adults","Effect of Self-initiated Perturbation-based Balance Training on the Postural Stability of Community-dwelling Older Adults with an Increased Risk of Falling: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Community-dwelling adults aged 60 years old or older\n* Able to communicate effectively in Cantonese or Mandarin\n* Able to walk independently on level ground for at least 30 minutes\n* Abbreviated Mental Test (Hong Kong version) scores≥6\n* Have fallen in the preceding year, have concerns about falling, or feel unsteady while walking or standing.\n\nExclusion Criteria:\n\n* Uncorrected vision or hearing impairment\n* Osteoporosis\n* Hip or knee replacement within the last year\n* Have musculoskeletal, cardiovascular, mental, or neurological disorders that preclude their participation in the assessment or intervention safety",{"count":256,"type":22},[25],"This is a single-blinded study. Participants will be randomly assigned to self-initiated perturbation-based balance training (SePBT) group or control (conventional balance training) group. Kinematic and Kinetic changes following SePBT group compared to control will be investigated.",[28],[343,344,345],"Perturbation","Step training","Falls","2025-02-20",{"date":348,"type":35},"2025-02-24",{"date":350,"type":35},"2024-11-06",{"date":166,"type":22},{"name":353,"class":42},"The Hong Kong Polytechnic University",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":43},"100567925","phase-1-evaluation-of-626-in-healthy-adult-subjects-100567925","NCT06674525","Evaluation of 626 in Healthy Adult Subjects","A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SSGJ-626 in Healthy Adult Subjects","Inclusion Criteria:\n\n* Able to understand protocol requirements and sign a written ICF.\n* Male or female subjects aged 18-45 years when signing the ICF.\n* Male subjects with body weight ≥ 50 kg, and female subjects with body weight ≥ 45 kg. Subjects with BMI between 18 and 28 kg\u002Fm2.\n* Subjects whose test results are normal, or abnormal without clinical significance as determined by the investigator.\n* Female subjects with childbearing potential and male subjects (and their female partners) must agree to take highly effective contraceptive measures.\n\nExclusion Criteria:\n\n* History of severe allergy, or with a history of allergy to the study treatment or related excipients.\n* With any clinically significant diseases prior to the screening visit.\n* Subjects with positive test results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibody, anti-human immunodeficiency virus (HIV) antibody.\n* History of of significant alcohol abuse.\n* History of significant drug abuse.\n* Subjects who have positive result for urine nicotine test at screening.\n* Pregnant, or nursing females.",{"count":362,"type":22},50,[55],"This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK and immunogenicity of SSGJ-626 in healthy adult subjects after single subcutaneous injection.",[28],"2024-12-05",{"date":368,"type":35},"2024-12-10",{"date":370,"type":35},"2024-12-02",{"date":372,"type":22},"2025-10",{"name":288,"class":70},{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":16,"sex":381,"minAge":18,"maxAge":154,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":43},"100565377","phase-1-a-study-evaluating-the-single-subcutaneous-injection-of-ebronucimab-in-chinese-healthy-male-subjects-100565377","NCT06641388","A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects","A Phase I Study Evaluating the Single Subcutaneous Injection of Ebronucimab With Different Production Processes in Chinese Healthy Male Subjects","Key Inclusion Criteria:\n\n* Weight: 60\\~80kg; Body mass index (BMI) ≥ 19 and ≤ 26 kg \u002Fm2 for healthy Chinese male subjects.\n* Subjects fully understand the purpose, content, process, and potential adverse events of the trial, voluntarily participate in the trial, and sign an informed consent form before any trial procedure begins.\n* Low density lipoprotein cholesterol (LDL-C) levels ≥ 1.8mmol\u002FL and ≤ 4.9mmol\u002FL during screening.\n* Subjects are able to communicate well with the investigator and understand the requirements of the study.\n\nKey Exclusion Criteria:\n\n* 12 months prior use of PCSK9 inhibitors treatment.\n* Allergic to the components of Ebronucimab and any monoclonal antibodies.\n* History of important organ transplantation (such as heart, lung, liver, kidney, etc.).\n* Abnormal vital signs during screening period and before randomization.\n* Drug abuse prior to screening.","MALE",{"count":177,"type":22},[55],"This is a phase I clinical study to evaluate the pharmacokinetics (PK) similarity of single dose subcutaneous injection of Ebronucimab with different production processes in Chinese healthy male subjects.",[28],[387,388],"phase I","healthy subjects","2024-10-12",{"date":391,"type":35},"2024-10-15",{"date":393,"type":22},"2024-11-04",{"date":395,"type":22},"2025-06-17",{"name":397,"class":70},"Akeso",{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":406,"briefSummary":407,"conditions":408,"keywords":409,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100564736","phase-1-a-phase-i-clinical-trial-of-jh013-injection-100564736","NCT06633055","A Phase I Clinical Trial of JH013 Injection","A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JH013 Injection in Healthy Subjects","Inclusion Criteria:\n\n* Healthy adult male or female aged 18-55 years (age including cut-off values);\n* There were no abnormalities in clinically significant vital signs, physical examination, laboratory tests, and 12-lead ECG;\n* Weight ≥ 50 kg for males and ≥45 kg for females; Body mass index (BMI) between 18.0 and 26 kg\u002Fm2 (including cut-off values, body mass index = weight\u002Fheight2);\n* Females of potential childbearing potential with a negative blood β-HCG test within 72 hours prior to dosing (postmenopausal women who have amenorrhea for at least 12 months are considered non-childbearing and women who are known to have undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or ligation, and a pregnancy test is not required);\n* Subjects understand and comply with the study process, participate voluntarily, and sign the informed consent form\n\nExclusion Criteria:\n\n* Subject has a history of malignancy prior to screening, or has been screened for malignancy, and the possibility of malignancy cannot be reasonably ruled out\n* Subject has a history of autoimmune disease prior to screening\n* γ interferon release assay results ≥ 2 times the upper limit of normal\n* Any history of infection requiring hospitalization or receiving antivirals, antibiotics, antifungals, antiparasitic drugs, or vaccinations within 4 weeks prior to the application of the study drug\n* Those who have positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV) antibody or syphilis antibody\n* Patients with a history of previous and\u002For current heart disease (including New York Heart Association Class III\u002FIV heart failure), gastrointestinal, renal, endocrine, neurological, autoimmune, hematologic (including pancytopenia, aplastic anemia or anaemia, etc.), metabolic (including diabetes), severe lung disease and psychiatric illness\n* History of organ transplantation: such as heart, lung, kidney, liver, or hematopoietic stem cell transplantation",{"count":220,"type":22},[55],"This is a phase I clinical trial with a single dose escalation to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JH013 injection in healthy subjects",[28],[410],"Dose escaltion","2024-10-07",{"date":413,"type":35},"2024-10-09",{"date":415,"type":22},"2024-10-31",{"date":417,"type":22},"2025-12-31",{"name":419,"class":42},"Biotech Pharmaceutical Co., Ltd.",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":4},"100563616","effects-of-kinesiotape-or-neuromuscular-taping-on-the-activation-of-the-transversus-abdominis-muscle-a-pilot-study-100563616","NCT06618482","Effects of Kinesiotape or Neuromuscular Taping on the Activation of the Transversus Abdominis Muscle. A Pilot Study","Inclusion Criteria:\n\n* The participants are members of the UVIGO who voluntarily participate in the study with an age between 18 and 35 years.\n* The participants are healthy subjects (men and women) of legal age.\n* All subjects must sign the informed consent prior to the experimentation.\n\nExclusion Criteria:\n\n* \\- Suffering from skin disorders, fragile skin or allergy to adhesive bandages.\n* Elite athletes.\n* Excessive skin hair in the region to apply the bandage.\n* Receive a bandage in the abdominal or lumbar region two weeks prior to the experiment.\n* History of orthopedic\u002Ftraumatic alterations in the lumbopelvic region (deformities, arthrodesis, arthropathy, muscle injuries, fracture or tendinopathy), neurological disorders (central or peripheral), systemic disorders, circulatory disorders (edema, heart failure, thrombosis, renal failure), or surgery in the abdominal-lumbar region in the last 6 months.\n* Perform abdominal or lumbar strength training 48 hours prior to the study.\n* Limitation greater than 50% in the flexion-extension range of motion of the lumbar spine.\n* Consumption of alcoholic beverages or medications 24 hours prior to the experimentation.\n* Pregnancy or having given birth in less than a year.","35 Years",{"count":428,"type":22},12,[25],"The use of adhesive bandages is a widely practiced technique in both clinical and sports settings. There is a great variety of materials used for bandaging, with multiple objectives: limiting movement, correcting joint positions, reducing pain, enhancing sports performance, and reducing the number of injuries.\n\nHowever, current knowledge about their potential effects is still limited, and more studies are needed to determine the most appropriate application parameters.\n\nFor this reason, the objective of the study for which we request your collaboration is to determine to what extent the application of an adhesive bandage (neuromuscular tape) can influence muscle facilitation through fiber recruitment and strength development, to improve performance during exercise.\n\nThe information derived from this research will provide a better understanding of the influence that an adhesive bandage (neuromuscular tape) can have on the neuromuscular system and on strength enhancement.",[28],[433,434,435,436],"Kinesiotape","Bandage","Transverse Abdominal","Abdominal Ultrasound","2024-09-25",{"date":439,"type":35},"2024-10-01",{"date":441,"type":22},"2024-09-30",{"date":443,"type":22},"2024-10-16",{"name":445,"class":42},"University of Vigo"]